Summary The clinical and immune modulatory effects of interleukin-2 (IL-2) and interferon (INF) 
Interleukin-2 (IL-2), a glycosylated polypeptide, was first described more than 10 years ago as T-cell growth factor in the supernatant of cultured lectin stimulated lymphocytes (Morgan et al., 1978) . In 1983 the production of recombinant IL-2 became possible (Taniguchi et al., 1983) and since then IL-2 has become widely available for use in clinical studies. IL-2 induces a heterogeneous population of T-lymphocytes (lymphokine-activated killer cells or LAK-cells) which act independently of MHC class I antigens and are able to lyse fresh tumour cells without prior antigen exposition (Grimm et al., 1983) , activates T-cells to produce antigen specific cytolytic and antiproliferative responses against tumour cells (Smith, 1988) , and induces the release of secondary cytokines such as interferon (INF) gamma and tumour necrosis factor (TNF) alfa from activated T-cells and macrophages (Stotter et al., 1989) .
INF alpha, a product of leucocytes, was initially identified through its antiviral activity (Isaacs & Lindenmann, 1957) . INF alpha also has antitumour activity, either by direct antiproliferative effects on tumour cells (Fidler et al., 1987) , or indirectly by the induction of MHC class I or tumour associated antigens on tumour cells (Brunda et al., 1987) .
The therapeutic potential of both IL-2 and INF alpha as single agents has been studied in renal cell carcinoma and melanoma. Published clinical trials of INF alpha have reported response rates between 10-17% in renal cell carcinoma and melanoma (Hersey et al., 1985; Quesada et al., 1985) . Phase II studies of IL-2 with or without LAK cells have reported tumour responses of 16-31 % in renal cell carcinoma and 14-26% in melanoma (Rosenberg et al., 1988; Fischer et al., 1988; Stahel et al., 1989; Dutcher et al., 1989; Bar et al., 1990) , although at the cost of considerable acute toxicity.
With the aim to increase tumour response and/or reduce IL-2 induced toxicity, clinical studies are currently under way using IL-2 in combination with other cytokines or with cytostatic agents. Our decision to study was based on three factors: (1) Either agent alone has antitumour activity against melanoma or renal cell carcinoma, (2) in combination, these two agents have a synergistic antitumour effect in the mouse model (Brunda et al., 1987) and (3) INF alfa-2a enhances the MHC class I and tumour associated antigen expression on the cell surface of tumour cells (Borden et al., 1988) (Figure 2) had a partial response, and two patients had a minor response (Table I ). The responses lasted from 1 to 7 months. Immune modulatory effects Lymphocyte subset determination and measurement of NKand LAK-activity were done on days 1 and 8 of cycles 1-4 and INF gamma and TNF alfa serum levels were determined on days 2-4 of cycles 1-4. During every treatment cycle, lymphopenia was observed on day 4 followed by a rebound lymphocytosis on day 8 (Figure 3) . CD16-and CD56-positive cells as indicators for activated lymphocytes and NK-cells increased 2.5-fold (P<0.01) and 2-fold (P<0.01) during cycle 1, and 1.8-fold (n.s.) or 2.6-fold respectively (P<0.05) during cycle 4 (Figure 4) .
In contrast to the consistent treatment induced increase of CD16 and CD56 pos. cells over the first four cycles; LAKand NK-activity increased during the first two cycles only, plateaued during the third cycle and even decreased (n.s.) during the fourth cycle ( Figure 5) .
Examination of treatment induced release of secondary cytokines showed no significant changes in TNF alpha levels while INF gamma levels decreased with successive cycles with a significant difference between the first and the third cycle of treatment (P<0.05). (Figure 6 ). (Klempner et al., 1990) . Prophylactic antibiotic therapy might thus be of advantage in further studies using IL-2.
We have previously described a self-limiting form of autoimmune thyroiditis with expression of HLA-DR on thyrocytes in patients undergoing combined IL-2 and INF alfa-2a therapy (Pichert et al., 1990 Final data on response rates with our regimen of IL-2 and INF alfa-2a will only be available when all data from the multicenter trial has been analysed. In part of the study, tumour response was only seen in patients with melanoma (two partial and two minor responses). Using the combination of IL-2 in INF alfa-2a, we and others found little effectivity in renal cell carcinoma (Lee et al., 1989) . These findings are in contrast to reports by Rosenberg et al., 1989 , who reported response rates of 17-41% in both melanoma and renal cell carcinoma with escalating doses of IL-2 (3-13.5 MU/m2 per day) and INF alfa-2a (9-18 MU/ms per day), suggesting a possible dose response relationship for the combination of IL-2 and INF alfa-2a. to a therapy-acquired unresponsiveness of lymphocytes (Maluish et al., 1983; Golub et al., 1982 (Tokuda et al., 1989; Brunda et al., 1986) . Thus the timing of INF alfa-2a application when given in combination with IL-2 might be important and these results should be taken into account in designing further studies.
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